A novel oral octreotide formulation was tested for efficacy and safety in a phase III, multicenter, open-label, dose-titration, baseline-controlled study in patients with acromegaly.

Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial

GIUSTINA , ANDREA;
2015-01-01

Abstract

A novel oral octreotide formulation was tested for efficacy and safety in a phase III, multicenter, open-label, dose-titration, baseline-controlled study in patients with acromegaly.
2015
Acromegaly; Adenoma; Administration; Oral; Adult; Aged; Antineoplastic Agents; Hormonal; Dose-Response Relationship; Drug; Female; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide; Treatment Outcome
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/14502
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 143
  • ???jsp.display-item.citation.isi??? 123
social impact